RecruitingNCT07062380

AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)

Prospective Validation of Multimodal Deep Learning Models for Predicting Recurrence Patterns in Early-Stage Hepatocellular Carcinoma After Resection: A Natural Treatment Cohort Stratification Study

Sponsor

Tongji Hospital

Enrollment

353 participants

Start Date

Jun 10, 2025

Study Type

OBSERVATIONAL

Conditions

Hepatectomy Hepatecellular Carcinoma

Summary

This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery. The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study uses artificial intelligence (AI) to analyze pre-surgery MRI scans and predict patterns of liver cancer recurrence after surgery, with the goal of better personalizing follow-up care and treatment decisions. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with early-stage liver cancer (hepatocellular carcinoma, HCC) and are scheduled for surgery to remove the tumor with the aim of a cure - You have an MRI scan of good quality taken within 1 month before your surgery - Your liver function is relatively preserved (Child-Pugh score of 7 or less) - You are in generally good health **You may NOT be eligible if...** - You have another active cancer (other than certain cured skin or cervical cancers) - Your post-surgery pathology shows a different type of cancer than originally diagnosed - You are pregnant or breastfeeding - You have had an organ transplant previously Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURECurative liver resection

Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.

PROCEDUREReal-world multimodal therapy

Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.